Gain Therapeutics (GANX) Common Equity (2020 - 2026)

Gain Therapeutics has reported Common Equity for 7 years, with the latest figure at $11.3 million in Q2 2026.

• On a quarterly basis, Common Equity rose 205.52% year-over-year to $11.3 million in Q2 2026; TTM through Jun 2026 was $11.3 million, a 205.52% increase from a year earlier, with the FY2025 full-year figure at $18.6 million, up 152.94% from the prior year.
• Common Equity was $11.3 million for Q2 2026 at Gain Therapeutics, down from $14.0 million in the prior quarter.
• The five-year high for Common Equity was $31.8 million in Q1 2022, with the low at $3.7 million in Q2 2025.
• Average Common Equity over 5 years is $13.5 million, with a median of $11.5 million recorded in 2024.
• The sharpest annual moves came in 2025 and 2026: Common Equity plunged 68.64% in 2025, then jumped 205.52% in 2026.
• Over 5 years, Common Equity stood at $18.9 million in 2022, then tumbled by 33.38% to $12.6 million in 2023, then tumbled by 41.65% to $7.3 million in 2024, then surged by 152.94% to $18.6 million in 2025, then slumped by 39.17% to $11.3 million in 2026.
• The last three Common Equity figures came in at $11.3 million (Q2 2026), $14.0 million (Q1 2026), and $18.6 million (Q4 2025), per Business Quant data.